Skip to main content
JAMA Network logoLink to JAMA Network
. 2021 Nov 29;79(1):86–87. doi: 10.1001/jamaneurol.2021.4391

Susceptibility-Weighted Imaging of Intravascular Lymphoma of the Central Nervous System

Megan B Richie 1,, Elan L Guterman 1, Maulik P Shah 1, Soonmee Cha 2
PMCID: PMC8630657  PMID: 34842897

Abstract

This case series examines susceptibility-weighted imaging in patients who had intravascular lymphoma of the central nervous system.


Intravascular lymphoma (IVL) is characterized by infiltration and proliferation of malignant B cells within small–blood vessel lumens. The central nervous system (CNS) is the most common primary site, and heterogeneous presentation results in diagnostic delay such that 60% of CNS presentations are diagnosed post mortem.1 Magnetic resonance imaging (MRI) patterns are consistent with microangiopathy, including infarctlike lesions, white matter lesions, leptomeningeal enhancement, masslike lesions, and hyperintense pontine lesions. However, half of patients with neurologic involvement have not shown specific brain lesions using traditional MRI sequences.2 Given the vascular pathophysiology of IVL, susceptibility-weighted imaging (SWI) sequences to detect microhemorrhage may have increased sensitivity; however, their diagnostic utility is poorly characterized. This case series describes clinical and radiographic characteristics of 6 patients with CNS IVL, emphasizing SWI.

Methods

We conducted a case series using medical record data from a convenience sample of 6 patients with biopsy-confirmed CNS IVL between June 2013 and February 2020. All patients underwent brain MRIs, including diffusion-weighted imaging, precontrast and postcontrast T1-weighted imaging, T2-weighted imaging, SWI, and fluid-attenuated inversion recovery (FLAIR) imaging. No software was used for data analysis.

Results

Four of the 6 patients were female; the median (IQR) age at diagnosis was 67 (55-72) years. Three patients were diagnosed by brain biopsy, 2 by skin biopsy, and 1 by autopsy. All patients had cerebrospinal fluid analysis; only 1 demonstrated a modest pleocytosis, 3 had unremarkable results of serum flow cytometry, and all had at least 1 negative result on flow cytometry.

Abnormal susceptibility was seen in all patients, occurring in both supratentorial and infratentorial gray and white matter, often punctate or gyriform, inconsistently associated with T2 hyperintensity and/or reduced diffusion (Figure). Abnormal susceptibility ranged in appearance and severity, from innumerable subcortical microhemorrhages (case 1), lobar macrohemorrhage (case 6), and a few punctate foci of microhemorrhage on SWI not appreciable on subsequent gradient echo sequences T2*-weighted imaging (case 2).

Figure. Axial Susceptibility-Weighted Imaging of All 6 Patients With Biopsy-Proven Intravascular Lymphoma.

Figure.

Patient 1 had numerous punctate to small clusters of microhemorrhages primarily located within the bilateral cerebral hemispheric subcortical white matter. Patient 2 had focal isolated gyriform microhemorrhage within the left parietal cortex. Patient 3 had a few foci of gyriform microhemorrhage within the right frontal cortices and scattered punctate microhemorrhage in the left frontal subcortical white matter. Patient 4 had scattered foci of gyriform microhemorrhage in bilateral cerebral cortices. Patient 5 had several punctate foci of microhemorrhage, some associated with T2 hyperintense lesions. Patient 6 had a large lobar macrohemorrhage in the left parietal lobe and several scattered microhemorrhage within the right cerebral hemisphere.

All patients demonstrated abnormal white matter T2 or FLAIR hyperintensities. Five patients demonstrated reduced diffusion, predominantly in small-vessel patterns. Four showed abnormal enhancements, often subtle, parenchymal, and involving gray or white matter.

Discussion

Among 6 patients with biopsy-proven CNS IVL, all patients had abnormal susceptibility identified on SWI and abnormal white matter hyperintensities on T2 or FLAIR. Other MRI sequences less consistently demonstrated abnormalities.

Abnormal SWI findings in patients with CNS IVL are not well characterized, and associations have been limited to single-case reports.3,4 In this series, areas of abnormal susceptibility did not consistently correspond with T2 hyperintensity or reduced diffusion, which was consistent with prior evidence and suggests microhemorrhage or intravascular thrombosis as a separate and potentially predominant imaging finding.4 This theory may partially account for the historical insensitivity of MRI in detecting CNS IVL.2 Widespread use of SWI in MRI protocols has increased detection of blood products and could contribute to improved diagnosis of CNS IVL if reliably adopted in its diagnostic evaluation.5 The superiority of SWI over gradient echo sequence T2*-weighted imaging in detecting microhemorrhage arises from enhancements, including 3-dimensional technique or multiple-echo time technique, to heighten sensitivity in comparison with gradient echo or T2* sequences. This is consistent with case 2 in our series, which demonstrated abnormal SWI lesions not appreciable on subsequent T2*-weighted sequences.

The small sample size and lack of controls limits this study, preventing estimation of sensitivity and specificity of SWI for IVL. Additionally, some patients were imaged at advanced stages of disease; however, this is typical of CNS IVL diagnosis.

In conclusion, patients with CNS IVL may demonstrate characteristic patterns of microhemorrhage and intravascular thrombosis on SWI. Although SWI abnormalities are seen in many neurologic conditions, their presence in the appropriate clinical context should prompt IVL consideration and subsequent tissue sampling, including blind skin biopsy as an alternative to brain biopsy. Such strategies may facilitate earlier diagnosis and improve outcomes.6

References

  • 1.Fonkem E, Lok E, Robison D, Gautam S, Wong ET. The natural history of intravascular lymphomatosis. Cancer Med. 2014;3(4):1010-1024. doi: 10.1002/cam4.269 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Brunet V, Marouan S, Routy J-P, et al. Retrospective study of intravascular large B-cell lymphoma cases diagnosed in Quebec: a retrospective study of 29 case reports. Medicine (Baltimore). 2017;96(5):e5985. doi: 10.1097/MD.0000000000005985 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Leclercq L, Mechtouff L, Hermier M, Cho T-H, Nighoghossian N, Ducray F. Intravascular large B-cell lymphoma mimicking cerebral amyloid angiopathy-related inflammation. Rev Neurol (Paris). 2018;174(4):265-266. doi: 10.1016/j.neurol.2017.06.023 [DOI] [PubMed] [Google Scholar]
  • 4.Tsuda Y, Oguri T, Sakurai K, Kajiguchi T, Kato H, Yuasa H. Low signal intensity lesions on brain susceptibility-weighted MRI in a patient with intravascular large B-cell lymphoma. Rinsho Shinkeigaku. 2017;57(9):504-508. doi: 10.5692/clinicalneurol.cn-001027 [DOI] [PubMed] [Google Scholar]
  • 5.Liu S, Buch S, Chen Y, et al. Susceptibility-weighted imaging: current status and future directions. NMR Biomed. 2017;30(4). doi: 10.1002/nbm.3552 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Ong Y-C, Kao H-W, Chuang W-Y, et al. Intravascular large B-cell lymphoma: a case series and review of literatures. Biomed J. 2021;44(4):479-488. doi: 10.1016/j.bj.2020.04.005 [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from JAMA Neurology are provided here courtesy of American Medical Association

RESOURCES